Clinical Trials - September 21, 2015
BioInvent expand planned clinical study
BioInvent International has announced that the company and its partner, the University of Pennsylvania, have decided to expand their planned clinical Phase II study with the antibody BI-505 by, among other things, including a control group. This will increase the study data quality and accelerate the path for approval of a potential new drug for […]
Uncategorized - March 19, 2015
BioInvent Focusing on Pediatric Cancer
Biotech company BioInvent plans to start clinical development of TB-403 for the treatment of pediatric cancer along with the Belgian biopharmabolaget Thrombogenics. A phase II/IIa program with TB-403 in patients with medulloblastoma is scheduled to start during the second half of the year 2015, BioInvent writes in a press release. BioInvent contributes half of the […]
Drug Development Pharma - May 30, 2014
BioInvent sells back to Alligator Bioscience
BioInvent has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. BioInvent has manufactured ADC-1013 (a FIND optimized n-CoDeR antibody) and the company has announced that it will fulfill the remaining CMC activities required to supply drug product to the First-in-Human study, expected to commence […]
Intellectual Property - November 13, 2013
BioInvent receives US patent for drug discovery technology
BioInvent International has announced that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T. The F.I.R.S.T. technology is a novel discovery method which allows for antibodies and disease targets to be identified simultaneously. BioInvent has used the technology successfully in several proprietary discovery projects and and offers F.I.R.S.T. […]
